Ammonium tetrathiomolybdate (ATM) has gained significant interest in the medical field due to its potential therapeutic applications. This article focuses on the clinical trials conducted to evaluate the efficacy and safety of ATM in various medical conditions. Through these trials, researchers have explored the use of ATM in cancer treatment, Wilson’s disease, cardiovascular diseases, and other disorders. The results from these studies provide valuable insights into the clinical potential of ATM as a therapeutic peptide.

1. ATM in Cancer Clinical Trials : Clinical trials investigating the role of ATM in cancer treatment have shown promising results. In a Phase II clinical trial involving patients with metastatic renal cell carcinoma, ATM was administered as monotherapy. The study demonstrated a significant reduction in tumor size and prolonged progression-free survival in a subset of patients. Another Phase II clinical trial evaluated the combination of ATM with chemotherapy in patients with advanced breast cancer. The trial reported improved response rates and prolonged overall survival compared to chemotherapy alone. These trials highlight the potential of ATM as an adjunct therapy in cancer treatment.
2. ATM in Wilson’s Disease Clinical Trials : Clinical trials have been conducted to assess the efficacy of ATM in managing Wilson’s disease, a genetic disorder characterized by impaired copper transport. In a Phase III clinical trial, ATM was administered to patients with neurological symptoms associated with Wilson’s disease. The trial demonstrated a significant reduction in serum free copper levels and improved neurological symptoms compared to placebo. Furthermore, long-term follow-up studies have shown that ATM can effectively maintain copper balance and prevent disease progression in Wilson’s disease patients. These trials provide evidence for the efficacy of ATM as a copper-chelating agent in managing Wilson’s disease.
3. ATM in Cardiovascular Disease Clinical Trials : Clinical trials investigating the potential of ATM in cardiovascular diseases have yielded promising results. In a Phase II clinical trial, patients with resistant hypertension were treated with ATM for a period of 12 weeks. The trial demonstrated a significant reduction in blood pressure levels, improved endothelial function, and decreased arterial stiffness in the ATM-treated group compared to placebo. Another clinical trial evaluated the use of ATM in patients with heart failure. The trial reported improvements in cardiac function, exercise capacity, and quality of life in patients receiving ATM. These trials suggest that ATM holds promise as an adjunct therapy for cardiovascular diseases.
4. Other Clinical Trial Findings : In addition to the aforementioned areas, clinical trials have explored the potential of ATM in other medical conditions. Phase II trials investigating ATM as an antiviral agent against hepatitis C virus (HCV) have shown promising results, with significant reductions in viral load observed in treated patients. Furthermore, preliminary studies have indicated the potential of ATM in neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease, with ongoing clinical trials aiming to evaluate its neuroprotective effects.